Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16273
Title: Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
Authors: Grasso, Carole;Anaka, Matthew;Hofmann, Oliver;Sompallae, Ramakrishna;Broadley, Kate;Hide, Winston;Berridge, Michael V;Cebon, Jonathan S;Behren, Andreas;McConnell, Melanie J
Issue Date: 9-Sep-2016
EDate: 2016-09-09
Citation: BMC Cancer 2016; 16(1): 726
Abstract: BACKGROUND: The heterogeneity and tumourigenicity of metastatic melanoma is attributed to a cancer stem cell model, with CD133 considered to be a cancer stem cell marker in melanoma as well as other tumours, but its role has remained controversial. METHODS: We iteratively sorted CD133+ and CD133- cells from 3 metastatic melanoma cell lines, and observed tumourigenicity and phenotypic characteristics over 7 generations of serial xeno-transplantation in NOD/SCID mice. RESULTS: We demonstrate that iterative sorting is required to make highly pure populations of CD133+ and CD133- cells from metastatic melanoma, and that these two populations have distinct characteristics not related to the cancer stem cell phenotype. In vitro, gene set enrichment analysis indicated CD133+ cells were related to a proliferative phenotype, whereas CD133- cells were of an invasive phenotype. However, in vivo, serial transplantation of CD133+ and CD133- tumours over 7 generations showed that both populations were equally able to initiate and propagate tumours. Despite this, both populations remained phenotypically distinct, with CD133- cells only able to express CD133 in vivo and not in vitro. Loss of CD133 from the surface of a CD133+ cell was observed in vitro and in vivo, however CD133- cells derived from CD133+ retained the CD133+ phenotype, even in the presence of signals from the tumour microenvironment. CONCLUSION: We show for the first time the necessity of iterative sorting to isolate pure marker-positive and marker-negative populations for comparative studies, and present evidence that despite CD133+ and CD133- cells being equally tumourigenic, they display distinct phenotypic differences, suggesting CD133 may define a distinct lineage in melanoma.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16273
DOI: 10.1186/s12885-016-2759-2
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/27613604
Type: Journal Article
Subjects: AC133 antigen
Melanoma
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
art%3A10.1186%2Fs12885-016-2759-2.pdf3.67 MBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.